Logo image of OMER

OMEROS CORP (OMER) Stock Price, Quote, News and Overview

NASDAQ:OMER - Nasdaq - US6821431029 - Common Stock

9.15  -0.18 (-1.93%)

After market: 9.15 0 (0%)

OMER Quote and Key Statistics

OMEROS CORP

NASDAQ:OMER (1/21/2025, 8:18:34 PM)

After market: 9.15 0 (0%)

9.15

-0.18 (-1.93%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High13.6
52 Week Low2.61
Market Cap530.24M
Shares57.95M
Float55.37M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-08 2009-10-08

OMER Financial Highlights

Industry RankSector Rank
PM (TTM) N/A
ROA -42.93%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%6.67%
Sales Q2Q%N/A
EPS 1Y (TTM)-821.88%
Revenue 1Y (TTM)N/A
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OMER Performance and Technical Analysis

Chartmill TA Rating
Chartmill Setup Rating

OMER short term performance overview.The bars show the price performance of OMER in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80 100

OMER long term performance overview.The bars show the price performance of OMER in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200
OMEROS CORP / OMER Daily stock chart

OMER Ownership and Analysts

Ownership
Inst Owners43.35%
Ins Owners4.42%
Short Float %15.24%
Short Ratio6.88
Analysts
Analysts80
Price Target43.86 (379.34%)
EPS Next Y-57.88%
Revenue Next YearN/A
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

OMER Latest News and Analysis

About OMER

Company Profile

OMER logo image Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 198 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Company Info

OMEROS CORP

201 Elliott Avenue West

Seattle WASHINGTON 98119 US

CEO: Gregory A. Demopulos

Employees: 198

Company Website: https://www.omeros.com/

Investor Relations: https://investor.omeros.com/

Phone: 12066765000

OMER Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 72.99 704.73B
NVO NOVO-NORDISK A/S-SPONS ADR 27.38 359.88B
JNJ JOHNSON & JOHNSON 14.47 356.69B
MRK MERCK & CO. INC. 16.17 243.45B
AZN ASTRAZENECA PLC-SPONS ADR 17.84 210.75B
NVS NOVARTIS AG-SPONSORED ADR 13.37 199.39B
PFE PFIZER INC 10.33 150.97B
SNY SANOFI-ADR 12.43 129.60B
BMY BRISTOL-MYERS SQUIBB CO 48.75 115.69B
ZTS ZOETIS INC 29.09 75.58B
GSK GSK PLC-SPON ADR 8.26 68.92B
TAK TAKEDA PHARMACEUTIC-SP ADR 21.83 41.53B